Charles River Laboratories International 

$189.74
91
+$2.23+1.19% 今天

統計

當日最高
191.27
當日最低
186.65
52週高點
228.88
52週低點
143.06
成交量
31,468,825
平均成交量
-
市值
9.34B
本益比
-
股息殖利率
-
股息
-

即將到來

財報

12Aug預期
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
下一步
1.94
2.34
2.73
3.12
預期EPS
2.73186
實際EPS
不適用

財務

-3.59%利潤率
未盈利
2020
2021
2022
2023
2024
2025
8.03B營收
-288.68M淨利

分析師評級

208.63平均目標價
最高預估為 265.00。
來自過去6個月內的 8 則評分。這不是投資建議。
買入
63%
持有
38%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 CRL 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Show more...
執行長
Ms. Birgit Girshick
員工
18700
國家
美國
ISIN
US1598641074

上市

0 Comments

分享你的想法

FAQ

Charles River Laboratories International 今天的股價是多少?
CRL 目前價格為 $189.74 USD,過去 24 小時上漲了 +1.19%。在圖表上更密切關注 Charles River Laboratories International 股價表現。
Charles River Laboratories International 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Charles River Laboratories International 的股票以代號 CRL 進行交易。
Charles River Laboratories International 的股價在上漲嗎?
CRL 股票較上週上漲 +1.82%,本月上漲 +25.84%,過去一年 Charles River Laboratories International 上漲 +27.02%。
Charles River Laboratories International 的市值是多少?
今天 Charles River Laboratories International 的市值為 9.34B
Charles River Laboratories International 下一次財報日期是什麼時候?
Charles River Laboratories International 將於 August 12, 2026 公布下一次財報。
Charles River Laboratories International 上一季度的財報如何?
CRL 上一季度的財報為每股 2.06 USD,預估為 1.94 USD,帶來 +5.99% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Charles River Laboratories International 去年的營收是多少?
Charles River Laboratories International 去年的營收為 8.03BUSD。
Charles River Laboratories International 去年的淨利是多少?
CRL 去年的淨收益為 -288.68MUSD。
Charles River Laboratories International 有多少名員工?
截至 June 15, 2026,公司共有 18,700 名員工。
Charles River Laboratories International 位於哪個產業?
Charles River Laboratories International從事於Health & Wellness產業。
Charles River Laboratories International 何時完成拆股?
Charles River Laboratories International 最近沒有進行任何拆股。
Charles River Laboratories International 的總部在哪裡?
Charles River Laboratories International 的總部位於 美國 的 Wilmington。